Related Experiment Video
Updated: Aug 30, 2025
09:31
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
9.3K
Circulating biomarkers in malignant pleural mesothelioma
Giuseppe Viscardi1,2, Davide Di Natale3, Morena Fasano1
1Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", 80131 Naples, Italy.
Exploration of Targeted Anti-Tumor Therapy
|September 1, 2022
Summary
Liquid biopsy shows promise as a non-invasive tool for diagnosing malignant pleural mesothelioma (MPM) in asbestos-exposed individuals. This approach could improve early detection, prognosis assessment, and treatment response prediction for this aggressive cancer.
Area of Science:
- Oncology
- Biomarkers
- Diagnostic Technologies
Background:
- Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related cancer with poor prognosis, often diagnosed at advanced stages.
- Current diagnostic methods, including radiological and pathological assessments, can be challenging and ineffective for early detection.
- There is a critical need for non-invasive biomarkers for screening, prognosis, and treatment prediction in precision oncology.
Purpose of the Study:
- To review the current understanding and potential applications of liquid biopsy in the context of malignant pleural mesothelioma.
- To evaluate the utility of liquid biopsy as a diagnostic and prognostic tool for MPM.
Main Methods:
- Literature review of studies on liquid biopsy in malignant pleural mesothelioma.
- Analysis of current research on non-invasive biomarkers for MPM screening, diagnosis, and prognosis.
Main Results:
- Liquid biopsy offers a promising non-invasive approach for MPM detection and management.
- Potential applications include early screening in asbestos-exposed populations and prognostic assessment.
- Further validation is needed to establish its role in predicting treatment response.
Conclusions:
- Liquid biopsy represents a significant advancement in the search for reliable non-invasive biomarkers for malignant pleural mesothelioma.
- Its application could enhance early diagnosis, prognosis evaluation, and personalized treatment strategies for MPM patients.
